• 1
    Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006;12:1192-1204.
  • 2
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; for American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
  • 3
    Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54:20-27.
  • 4
    Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012;56:1622-1630.
  • 5
    McKenna GJ, Ruiz R, Onaca N, Campsen J, Klintmalm E, Levy MF, et al. The impact of timing in sirolimus conversion for renal insufficiency in liver transplant recipients [abstract]. Liver Transpl 2011;17(suppl 1):A84.
  • 6
    Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or −2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-468.e1.
  • 7
    Coilly A, Roche B, Dumortier J, Botta-Fridlund D, Leroy V, Pageaux PG, et al. Efficacy and safety of protease inhibitors for hepatitis C recurrence after liver transplantation: a first multicentric experience [abstract]. Hepatology 2012;56(suppl 1):194A.